Trial Profile

A study on Pegasys or PegIFN?-2b plus Ribavirin in the treatment of non-responsive Chronic Hepatitis C patients

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

21 May 2012 Planned end date changed from 1 Dec 2011 to 31 Dec 2012 as reported by Chinese Clinical Trial Register.
06 Dec 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com